ESMO: AZ, Merck's Lynparza brings precision medicine to prostate cancer with 'game-changer' results

30th September 2019 Uncategorised 0

AstraZeneca and Merck are working hard to bring their PARP inhibitor Lynparza into the prostate cancer arena, and they laid out a second case with new data Monday. Among previously treated metastatic, castration-resistant prostate cancer patients with one of three genetic mutations, Lynparza cut the risk of disease progression or death by a whopping 66%.

More: ESMO: AZ, Merck's Lynparza brings precision medicine to prostate cancer with 'game-changer' results
Source: fierce